Dasatinib: uses, dosing, side effects & brands
Dasatinib is a kinase inhibitor sold in the U.S. under 2 brand and generic names, for lymphoid leukemia and myeloid leukemia. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Drug class
- Kinase Inhibitor
- Treats
- Lymphoid Leukemia and Myeloid Leukemia
- Available as
- Tablet
- Sold as
- 2 products — Sprycel and Phyrago
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
- What the pharmacy pays
- about $839 for a 30-count supply — not your price
How dasatinib is dosed
From the FDA label for Phyrago (application NDA216099). Other dasatinib products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Chronic phase CML in adults: 100 mg orally once daily. ( 2 ) Accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults: 140 mg orally once daily. ( 2 ) Chronic phase CML and ALL in pediatrics: starting dose based on body weight. ( 2 ) Administer with or without a meal. Do not crush, cut, or chew tablets. ( 2 ) 2.1 Recommended Dosage in Adult Patients The recommended starting dosage of PHYRAGO for chronic phase CML in adults is 100 mg administered orally once daily. The recommended starting dosage of PHYRAGO for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults is 140 mg administered orally once daily. Swallow PHYRAGO whole. Do not crush, cut, or chew the tablets. PHYRAGO can be taken with or without a meal, either in the morning or in the evening. 2.2 Recommended Dosage in Pediatric Patients with CML or Ph+ ALL The recommended starting dosage for pediatrics is based on body weight as shown in Table 1. The recommended dose should be administered orally once daily with or without food. Recalculate the dose every 3 months based on changes in body weight, or more often if necessary. Do not crush, cut, or chew tablets. Swallow tablets whole. There are additional administration considerations for pediatric patients who have difficulty swallowing tablets whole [see Use in Specific Populations ( 8.4 )]. Table 1: Dosage of PHYRAGO…
Dasatinib side effects
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Myelosuppression [see Dosage and Administration ( 2.5 ) and Warnings and Precautions ( 5.1 )] . Bleeding-related events [see Warnings and Precautions ( 5.2 )] . Fluid retention [see Warnings and Precautions ( 5.3 )] . Cardiovascular toxicity [see Warnings and Precautions ( 5.4 )] . Pulmonary arterial hypertension [see Warnings and Precautions ( 5.5 )] . QT prolongation [see Warnings and Precautions ( 5.6 )] . Severe dermatologic reactions [see Warnings and Precautions ( 5.7 )] . Tumor lysis syndrome [see Warnings and Precautions ( 5.8 )] . Effects on growth and development in pediatric patients [see Warnings and Precautions ( 5.10 )] . Hepatotoxicity [see Warnings and Precautions ( 5.11 )] . Most common adverse reactions (≥15%) in patients receiving dasatinib as single-agent therapy included myelosuppression, fluid retention events, diarrhea, headache, skin rash, hemorrhage, dyspnea, fatigue, nausea, and musculoskeletal pain. ( 6 ) Most common adverse reactions (≥30%) in pediatric patients receiving dasatinib in combination with chemotherapy included mucositis, febrile neutropenia, pyrexia, diarrhea, nausea, vomiting, musculoskeletal pain, abdominal pain, cough, headache, rash, fatigue, constipation, arrhythmia, hypertension, edema, infections (bacterial,…
Who shouldn’t take dasatinib
None. None. ( 4 )
Dasatinib drug interactions
Strong CYP3A4 Inhibitors: Dose reduction may be necessary. ( 2.3 , 7.1 ) Strong CYP3A4 Inducers: Dose increase may be necessary. ( 2.3 , 7.1 ) Antacids: Avoid concomitant use. ( 2.3 , 7.1 ) 7.1 Effect of Other Drugs on Dasatinib Strong CYP3A4 Inhibitors The coadministration with strong CYP3A inhibitors may increase dasatinib concentrations [see Clinical Pharmacology ( 12.3 )] . Increased dasatinib concentrations may increase the risk of toxicity. Avoid concomitant use of strong CYP3A4 inhibitors. If concomitant administration of a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction [see Dosage and Administration ( 2.3 )] . Strong CYP3A4 Inducers The coadministration of PHYRAGO with strong CYP3A inducers may decrease dasatinib concentrations [see Clinical Pharmacology ( 12.3 )] . Decreased dasatinib concentrations may reduce efficacy. Consider alternative drugs with less enzyme induction potential. If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . Antacids Avoid concomitant use of PHYRAGO with antacids. If concomitant use of an antacid cannot be avoided, administer the antacid at least 2 hours prior to or 2 hours after the dose of PHYRAGO [see Dosage and Administration ( 2.3 )] . Concomitant use with antacids decreases dasatinib plasma concentrations [see Clinical Pharmacology ( 12.3 )] , which may reduce PHYRAGO efficacy. 7.1 Effect of Other Drugs on Dasatinib Strong CYP3A4 Inhibitors The coadministration with strong CYP3A inhibitors may increase dasatinib concentrations [see Clinical Pharmacology ( 12.3 )] . Increased dasatinib concentrations may increase the risk of toxicity. Avoid concomitant use of strong CYP3A4 inhibitors. If concomitant administration of a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction [see Dosage and Administration ( 2.3 )] . Strong CYP3A4 Inducers The coadministration of PHYRAGO with strong CYP3A inducers may decrease dasatinib concentrations [see Clinical Pharmacology ( 12.3 )] . Decreased dasatinib concentrations may reduce efficacy. Consider alternative drugs with less enzyme induction potential. If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . Antacids Avoid concomitant use of PHYRAGO with antacids. If concomitant use of an antacid cannot be avoided, administer the antacid at least 2 hours prior to or 2 hours after the dose of PHYRAGO [see Dosage and Administration ( 2.3 )] . Concomitant use with antacids decreases dasatinib plasma concentrations [see Clinical Pharmacology ( 12.3 )] , which may reduce PHYRAGO efficacy.
Every dasatinib product we track (2)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Tablet | Generic | $839 | View → | |
| 2 | Not yet rated | Prescription | Tablet | Generic | $839 | View → |
What dasatinib pills look like
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
Can you crush or split dasatinib?
At least one dasatinibproduct is labelled to be swallowed whole — crushing an extended-release tablet releases the whole day’s dose at once. Which applies depends on the form you were given.
What each dasatinib label says about crushing, splitting and chewingHow long dasatinib keeps
No dasatinib label we read sets a separate limit for after opening, but they do specify how it must be stored — and the stability behind any date assumes those conditions.
Does dasatinib expire? The in-use limits and storage rules from its labelsDasatinib and breastfeeding
From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.
Full LactMed record for dasatinib: levels in milk, effects in breastfed infants, and the drugs it would consider insteadAlthough one breastfed infant apparently experienced no adverse effects during maternal use of dasatinib, no long-term data are available. Because dasatinib and its metabolite are more than 90% bound to plasma proteins, the amounts in milk are likely to be low. However, there is little published experience with dasatinib during breastfeeding, and an alternate drug may be preferred, especially while nursing a newborn or preterm infant. National Comprehensive Cancer Network guidelines recommend avoiding breastfeeding during dasatinib therapy and the manufacturer recommends withholding breastfeeding until 2 weeks following the last dose.
National Institute of Child Health and Human Development, record revised July 19, 2021. LactMed states its information is not a substitute for professional judgement.
What people report to the FDA about dasatinib
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 9,474 reports naming dasatinib, and the FDA flagged 91% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- pleural effusion1,224 reports
- drug intolerance563 reports
- drug resistance537 reports
- diarrhoea466 reports
- dyspnoea435 reports
- thrombocytopenia433 reports
- pyrexia407 reports
- malignant neoplasm progression402 reports
Read these as a signal, not a rate. A report does not mean dasatinib caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved August 25, 2026.
Related calculators
Frequently asked questions
What is dasatinib?
Phyrago (Dasatinib) is a kinase inhibitor used to treat Lymphoid Leukemia, Myeloid Leukemia.
What kind of drug is dasatinib?
The FDA classifies dasatinib as a kinase inhibitor. Kinase inhibitors block protein kinases, the enzymes that relay 'grow and divide' signals inside cells. By shutting down the overactive kinase signals that a tumor depends on, they help slow or stop cancer cells from multiplying. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.
Can you take dasatinib with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run dasatinib against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is dasatinib sold under?
We track 2 dasatinib-containing products in the U.S.: Sprycel and Phyrago. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does dasatinib come in?
Across the brands we track, dasatinib is currently marketed as tablet, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic dasatinib?
We do not currently list a generic-labelled dasatinib product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Dasatinib: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/dasatinib
- MLA
- “Dasatinib: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/dasatinib.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for dasatinib on DailyMed (NIH) ↗.